本帖最后由 老马 于 2013-3-13 13:43 编辑
, e9 c4 H- N$ X/ c& Q$ A' `$ \' `# Y
健择（吉西他滨）+顺铂+阿瓦斯汀
7 R5 ~5 J4 g$ C Gemzar +Cisplatin + Avastin5 T+ ~$ q0 o2 S) n4 B1 q# ]
http://annonc.oxfordjournals.org/content/21/9/1804.full$ [5 u9 K5 H# `6 c: ~" W
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 N2 @) L3 }: t# \ z( k" m% p/ A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 K x' ^4 K5 ?0 A1 |$ dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 3 C+ m# C$ ~: T' Y5 n8 p5 d% ]
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1015)
) y% w. E/ H" g, `( t8 I# A华为网盘附件：
" O1 p$ q; b8 N【华为网盘】ava.JPG% N, h1 P8 K( `6 { I
|
显身卡
